Skip to main content
Addgene

pcDNA3.1(-)-mIFNa2
(Plasmid #135098)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 135098 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pcDNA3.1(-)
  • Backbone size w/o insert (bp) 5430
  • Total vector size (bp) 6022
  • Vector type
    Mammalian Expression
  • Selectable markers
    Neomycin (select with G418)

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    mIFN-α2
  • Alt name
    Ifa2
  • Species
    M. musculus (mouse)
  • Insert Size (bp)
    626
  • Entrez Gene
    Ifna2 (a.k.a. Ifa2)
  • Promoter CMV

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site NotI (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer T7 primer
  • 3′ sequencing primer BGH Reverse Primer
  • (Common Sequencing Primers)

Resource Information

  • Supplemental Documents
  • A portion of this plasmid was derived from a plasmid made by
    mIFNa insert cloned from plasmid RDC2321 (R&D Systems)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pcDNA3.1(-)-mIFNa2 was a gift from Pablo Penaloza-MacMaster (Addgene plasmid # 135098 ; http://n2t.net/addgene:135098 ; RRID:Addgene_135098)
  • For your References section:

    Early type I IFN blockade improves the efficacy of viral vaccines. Palacio N, Dangi T, Chung YR, Wang Y, Loredo-Varela JL, Zhang Z, Penaloza-MacMaster P. J Exp Med. 2020 Dec 7;217(12). pii: 152035. doi: 10.1084/jem.20191220. 10.1084/jem.20191220 PubMed 32820330